CMS opens comment for 2027 Medicare drug price negotiation program

CMS published draft guidance for the second year of the Inflation Reduction Act's Medicare Drug Price Negotiation Program, setting the stage for 2027 selections. The agency is requesting public comment on the negotiation framework, including methodologies for selecting drugs and determining maximum fair prices. Drugs subject to negotiation for the 2027 cycle will be announced later this year, with negotiated prices set to take effect in 2028. The draft guidance and comment period indicate ongoing implementation of the program's controversial price-control provisions, which will impact Part D and Part B drug reimbursement. Practices should monitor the comment period for potential impacts on specialty drug access and reimbursement for 2027.